Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee.; LEADER Trial Investigators..

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

2.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators., Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

3.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

ORIGIN Trial Investigators., Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

4.

The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.

Rosenstock J, Banarer S, Fonseca VA, Inzucchi SE, Sun W, Yao W, Hollis G, Flores R, Levy R, Williams WV, Seckl JR, Huber R; INCB13739-202 Principal Investigators..

Diabetes Care. 2010 Jul;33(7):1516-22. doi: 10.2337/dc09-2315. Epub 2010 Apr 22.

5.

Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial.

Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler HP; PHX1149-PROT202 Study Group..

Diabetes Obes Metab. 2010 Apr;12(4):348-55. doi: 10.1111/j.1463-1326.2010.01195.x.

PMID:
20380656
6.

Glucose control and vascular complications in type 2 diabetes.

Banarer S.

N Engl J Med. 2009 May 7;360(19):2031; author reply 2032. doi: 10.1056/NEJMc090262. No abstract available.

8.

Hypoglycemia in type 2 diabetes.

Banarer S, Cryer PE.

Med Clin North Am. 2004 Jul;88(4):1107-16, xii-xiii. Review.

PMID:
15308392
9.

Ximelagatran versus warfarin after total knee replacement.

Banarer S.

N Engl J Med. 2004 Feb 5;350(6):616-7; author reply 616-7. No abstract available.

11.

Initial management of glycemia in type 2 diabetes.

Banarer S.

N Engl J Med. 2003 Feb 20;348(8):760-1; author reply 760-1. No abstract available.

12.
13.
14.

Elevated endogenous cortisol reduces autonomic neuroendocrine and symptom responses to subsequent hypoglycemia.

McGregor VP, Banarer S, Cryer PE.

Am J Physiol Endocrinol Metab. 2002 Apr;282(4):E770-7.

15.

Postmenopausal hormone-replacement therapy.

Banarer S.

N Engl J Med. 2002 Jan 3;346(1):63-5. No abstract available.

PMID:
11799955

Supplemental Content

Loading ...
Support Center